Berkeley Capital Partners LLC Sells 433 Shares of Johnson & Johnson (JNJ)

Berkeley Capital Partners LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 4.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,187 shares of the company’s stock after selling 433 shares during the period. Johnson & Johnson makes up approximately 0.7% of Berkeley Capital Partners LLC’s investment portfolio, making the stock its 23rd largest position. Berkeley Capital Partners LLC’s holdings in Johnson & Johnson were worth $1,315,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in JNJ. Meeder Asset Management Inc. increased its holdings in shares of Johnson & Johnson by 29.1% during the 4th quarter. Meeder Asset Management Inc. now owns 98,256 shares of the company’s stock worth $12,679,000 after buying an additional 22,157 shares during the last quarter. QUANTRES ASSET MANAGEMENT Ltd purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $829,000. Vanguard Group Inc boosted its position in shares of Johnson & Johnson by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock worth $29,490,100,000 after purchasing an additional 3,235,861 shares during the period. Wells Trecaso Financial Group LLC boosted its position in shares of Johnson & Johnson by 1.0% during the 3rd quarter. Wells Trecaso Financial Group LLC now owns 41,289 shares of the company’s stock worth $5,705,000 after purchasing an additional 420 shares during the period. Finally, First Fiduciary Investment Counsel Inc. boosted its position in shares of Johnson & Johnson by 2.4% during the 3rd quarter. First Fiduciary Investment Counsel Inc. now owns 143,732 shares of the company’s stock worth $19,859,000 after purchasing an additional 3,407 shares during the period. Institutional investors own 66.91% of the company’s stock.

NYSE:JNJ opened at $136.91 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13. The company has a market cap of $368.09 billion, a P/E ratio of 16.74, a P/E/G ratio of 2.37 and a beta of 0.67. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.07. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. The firm had revenue of $20.02 billion during the quarter, compared to analysts’ expectations of $19.55 billion. During the same quarter last year, the company posted $2.06 EPS. The firm’s quarterly revenue was up .1% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 8.6 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 11th. Shareholders of record on Tuesday, May 28th will be given a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 2.78%. The ex-dividend date of this dividend is Friday, May 24th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.90. Johnson & Johnson’s dividend payout ratio (DPR) is currently 44.01%.

A number of research firms recently weighed in on JNJ. Wells Fargo & Co reaffirmed an “outperform” rating and set a $157.00 price objective (up previously from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. BMO Capital Markets increased their price objective on shares of Johnson & Johnson from $154.00 to $157.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price objective for the company in a research report on Wednesday, March 27th. Credit Suisse Group increased their price objective on shares of Johnson & Johnson from $151.00 to $152.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Finally, Raymond James increased their price objective on shares of Johnson & Johnson from $145.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Buy” and a consensus price target of $146.90.

TRADEMARK VIOLATION WARNING: “Berkeley Capital Partners LLC Sells 433 Shares of Johnson & Johnson (JNJ)” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://transcriptdaily.com/2019/05/16/berkeley-capital-partners-llc-sells-433-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: What is a back-end load?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.